Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab.
checkpoint inhibitors
extragenital lichen sclerosus et atrophicus
ipilimumab
malignant melanoma
metastatic
nivolumab
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
06
2020
accepted:
25
08
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors.
Identifiants
pubmed: 33117707
doi: 10.3389/fonc.2020.573527
pmc: PMC7577175
doi:
Types de publication
Case Reports
Langues
eng
Pagination
573527Informations de copyright
Copyright © 2020 Seyed Jafari, Feldmeyer and Hunger.
Références
Clin Exp Dermatol. 2020 Apr;45(3):350-352
pubmed: 31498907
Am J Clin Dermatol. 2013 Feb;14(1):27-47
pubmed: 23329078
Clin Exp Dermatol. 2019 Mar;44(2):e22-e23
pubmed: 30430637
J Eur Acad Dermatol Venereol. 2012 Feb;26(2):207-12
pubmed: 22280508
Curr Oncol Rep. 2018 Mar 23;20(3):29
pubmed: 29569208
J Dermatol. 2015 Mar;42(3):333-4
pubmed: 25615429
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Invest Dermatol. 2012 Mar;132(3 Pt 1):658-66
pubmed: 22113482